Search engine for discovering works of Art, research articles, and books related to Art and Culture
Javascript must be enabled to continue!
HER2 Amplification in Hydatidiform mole patients
View through CrossRef
Hydatidiform mole is an abnormal pregnancy in which the placenta contains grape cell like vesicles (small sacs) , that are usually visible with the naked eye .Patients and methods : This study was carried out in Laboratories of College of Science, Wasit University , AL Zahraa and AL Karma Teaching Hospitals, from October 2014 to April 2015. The study included twenty Hydatidiform mole patients were taken randomly, and six non hydatidiform mole patients as control group. The patients with HM included 10 samples of complete H mole , and 10 samples of partial H mole. Chromogenic In Situ Hybridization (CISH) technique was used to detect the amplification of HER2 gene.Results: Regarding the HER2 amplification (over-expression of HER2) was significantly more frequent in H mole patients than in control (p≤0.05), also the same difference was indicated between complete H mole and control group. As well as between partial H mole and control group . While, HER2 amplification did not differ between complete H mole and partial H mole (p≤0.05) .
Title: HER2 Amplification in Hydatidiform mole patients
Description:
Hydatidiform mole is an abnormal pregnancy in which the placenta contains grape cell like vesicles (small sacs) , that are usually visible with the naked eye .
Patients and methods : This study was carried out in Laboratories of College of Science, Wasit University , AL Zahraa and AL Karma Teaching Hospitals, from October 2014 to April 2015.
The study included twenty Hydatidiform mole patients were taken randomly, and six non hydatidiform mole patients as control group.
The patients with HM included 10 samples of complete H mole , and 10 samples of partial H mole.
Chromogenic In Situ Hybridization (CISH) technique was used to detect the amplification of HER2 gene.
Results: Regarding the HER2 amplification (over-expression of HER2) was significantly more frequent in H mole patients than in control (p≤0.
05), also the same difference was indicated between complete H mole and control group.
As well as between partial H mole and control group .
While, HER2 amplification did not differ between complete H mole and partial H mole (p≤0.
05) .
Related Results
Abstract P4-15-07: HER2 positive (HER2/CEP17 ratio≥2.0) invasive mammary carcinomas with average <4.0 HER2 and <2.0 CEP17 signals/cell: Clinicopathologic features, correlation with HER2 immunohistochemistry and response to neoadjuvant chemot
Abstract P4-15-07: HER2 positive (HER2/CEP17 ratio≥2.0) invasive mammary carcinomas with average <4.0 HER2 and <2.0 CEP17 signals/cell: Clinicopathologic features, correlation with HER2 immunohistochemistry and response to neoadjuvant chemot
Abstract
Background: ASCO/CAP guidelines for the determination of HER2 amplification have recently been revised in an attempt to clarify which patients will benefit ...
HER2 expression dynamics and prognostic significance in the treatment of gastric cancer.
HER2 expression dynamics and prognostic significance in the treatment of gastric cancer.
4025
Background:
The human epidermal growth factor receptor 2 (HER2) expression undergoes changes during the treatment of gastric canc...
HER2-positive Apocrine Carcinoma of the Breast: A population-based Analysis of Treatment and Outcome
HER2-positive Apocrine Carcinoma of the Breast: A population-based Analysis of Treatment and Outcome
Abstract
Aims
Apocrine carcinoma of the breast (APO) expresses HER2 in 30-50% of cases. This study explored the clinicopathological features and outcome of HER2+ APO (HER2...
Abstract P3-09-02: The HER2 –positive subtypes by stage and race/ethnicity
Abstract P3-09-02: The HER2 –positive subtypes by stage and race/ethnicity
Abstract
HER2-positivity is often associated with poor survival. The purpose of this study is to determine if there are differences in mortality among the HER-positi...
Use of multimodal circulating tumor cell assay to detect HER2-ultralow and ER co-expression matched with single-cell chromosomal instability in metastatic breast cancer.
Use of multimodal circulating tumor cell assay to detect HER2-ultralow and ER co-expression matched with single-cell chromosomal instability in metastatic breast cancer.
e13024
Background:
Breast cancer is the second leading cause of cancer-related mortality among US women, with metastatic breast cancer...
Abstract P4-04-05: circHEACA promotes anti-HER2 drug resistance by HEACA-GRB7/AKT axis in HER2+ breast cancer patients
Abstract P4-04-05: circHEACA promotes anti-HER2 drug resistance by HEACA-GRB7/AKT axis in HER2+ breast cancer patients
Abstract
Background: Some HER2-positive (HER2+) breast cancer patient are resistant to anti-HER2 therapy, and the potential reasons of anti-HER2 drug resistance rema...
Abstract P2-11-12: Novel protocol combining metronomic nant-paclitaxel with HER2-targeted natural killer cells (innate immunotherapy) for HER2-positive metastatic breast cancer
Abstract P2-11-12: Novel protocol combining metronomic nant-paclitaxel with HER2-targeted natural killer cells (innate immunotherapy) for HER2-positive metastatic breast cancer
Abstract
Background. Natural killer (NK) cells are an important effector cell type for adoptive cancer immunotherapy. Phase 1 clinical trials in patients with advanc...
Abstract 1836: Patient-derived xenograft (PDX) models expressing HER2 reflect clinical responses to targeted HER2 inhibition
Abstract 1836: Patient-derived xenograft (PDX) models expressing HER2 reflect clinical responses to targeted HER2 inhibition
Abstract
Background While HER2-directed agents are most often used for treating breast cancer, there is increasing evidence that these therapies may be of value in o...